COMMUNIQUÉS West-GlobeNewswire

VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
19/04/2018
More than 1,600 subjects enrolled in PROTECT study Topline data expected mid-2019 CAMBRIDGE, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV ) (“VBI”) today announced the completion of [...]
Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting
19/04/2018
BOSTON, April 19, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO ), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that findings from two [...]
Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives
19/04/2018
- Company to terminate the ADAPT study – - Company has retained Stifel to provide advice on possible strategic alternatives – - Trading in the common stock to be transferred from Nasdaq to the OTCQB Venture Market - [...]
DLT Resolution Acquires Operating Assets of Canadian Telecom Service Provider
19/04/2018
Las Vegas, NV, April 19, 2018 (GLOBE NEWSWIRE) -- DLT Resolution Inc. (OTC: DLTI), a Distributed Ledger Technology (“Blockchain”) and Information Technology company that services the healthcare and telecommunications [...]
Athenex, Inc. Receives U.S. FDA Orphan Drug Designation for Oraxol for the Treatment of Angiosarcoma
19/04/2018
BUFFALO, N.Y., April 19, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
ICC Labs Enters Into Letter of Intent With Eurofarma Uruguay S.A., a Member of the Brazilian-Owned Multinational Eurofarma Group of Pharmaceutical Companies
19/04/2018
VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- ICC Labs Inc. (“ICC Labs” or the “Company”) (TSX-V: ICC ) (Frankfurt: 2Q9 ) is pleased to announce that one of its Uruguayan subsidiaries has entered into [...]
Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial
19/04/2018
Summit Therapeutics plc ("Summit" or the "Company") Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial Top-line Data On Track to be Reported During Q3 2018 Oxford, UK, and Cambridge, MA, US, 19 April [...]
Tetraphase Pharmaceuticals to Present Data at the 38th Annual Meeting of the Surgical Infection Society
19/04/2018
WATERTOWN, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH ), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening [...]
EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
19/04/2018
Conference Call Scheduled for 4:30 p.m. ET on Tuesday, May 8th WATERTOWN, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT ) (ASX:PVA), a specialty biopharmaceutical company [...]
NeuroMetrix Reports Q1 2018 Financial Results
19/04/2018
GlaxoSmithKline Collaboration is Quarter Highlight WALTHAM, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ), today reported financial and business highlights for the quarter ended March 31, [...]
Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer
19/04/2018
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM ), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders [...]
miRagen Therapeutics to Present New Preclinical Data at the Wound Healing Society and the Association for Research in Vision and Ophthalmology Annual Meetings
19/04/2018
BOULDER, Colo., April 19, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN ), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced [...]
Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
19/04/2018
Findings are the Basis for the HOPE-2 Clinical Trial LOS ANGELES, April 19, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR ) today announced that researchers found that repeat dosing of the company’s [...]
Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018
19/04/2018
Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS ), a clinical-stage immuno-oncology company developing [...]
XORTX Announces PKD Foundation Collaboration
19/04/2018
CALGARY, Alberta, April 19, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX) is pleased to announce that the PKD Foundation has recognized XORTX as a leader in advancing the [...]
Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial
19/04/2018
Top-line Data On-track to be Reported During Q3 2018 OXFORD, United Kingdom and CAMBRIDGE, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT ) (AIM:SUMM) announces the completion of [...]
Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018
19/04/2018
GAITHERSBURG, Md., April 19, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) will host a conference call on Thursday, May 3, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the first [...]
This Week in the News: A Curated Selection of the Best Media Coverage on PotNetwork Holdings, Inc.
19/04/2018
PotNetwork Holdings, Inc. featured in International Business Times, Small Cap Network, Born2Invest, Natural Way & Ultra Meds Global FT LAUDERDALE, Fla., April 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- [...]
Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
19/04/2018
-- Patients receiving GOCOVRI experienced long-term durability for up to two years -- -- Safety profile was consistent with previously-published controlled Phase 3 studies -- EMERYVILLE, Calif., April 19, 2018 (GLOBE [...]

Pages